<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FAMCICLOVIR</span><br/>(fam-ci'clo-vir)<br/><span class="topboxtradename">Famvir<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mg, 250 mg, 500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Prodrug to the antiviral agent penciclovir; may have an advantage over acyclovir because of its greater stability intracellularly
         in infected cells. Prevents viral replication by inhibition of DNA synthesis in herpes virus-infected cells, and has longer-lasting
         antiviral activity than acyclovir.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by decreasing pain and crusting of lesions followed by loss of vesicles, ulcers, and crusts. Interferes with DNA
         synthesis of herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) infections, varicella-zoster virus and cytomegalovirus.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of acute herpes zoster, genital herpes, recurrent episodes of genital herpes in immunocompromised adults. Suppression
         of recurrent episodes of genital herpes in immunocompetent adults.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to famciclovir, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic impairment, carcinoma, older adults, pregnancy (category B). Safety in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Herpes Zoster, Treatment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg q8h times 7 d, start within 4872 h of onset of rash<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 4059 mL/min: 500 mg q12h; 2039 mL/min: 500 mg q24h<br/><br/><span class="indicationtitle">Treatment of Recurrent Genital Herpes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 125 mg b.i.d. times 5 d<br/><br/><span class="indicationtitle">Suppression of Recurrent Genital Herpes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg b.i.d. for up to 1 y<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Reduce dosage in patients with reduced kidney function.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> somnolence, dizziness, paresthesias, fatigue, fever, rigors. <span class="typehead">Hematologic:</span> Purpura. <span class="typehead">GI:</span> Nausea, diarrhea, vomiting, constipation, anorexia, abdominal pain. <span class="typehead">Body as a Whole:</span> Pharyngitis, sinusitis, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Probenecid</b> may decrease elimination; famciclovir may increase <b>digoxin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract and rapidly converted to penciclovir in intestinal and liver tissue. <span class="typehead">Onset:</span> Median times to full crusting of lesions, loss of vesicles, loss of ulcers, and loss of crusts were 6, 5, 7, and 19 d, respectively;
      median time to loss of acute pain was 21 d. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Distributes into breast milk of animals. <span class="typehead">Metabolism:</span> Metabolized in liver and intestinal tissue to penciclovir, which is the active antiviral agent. <span class="typehead">Elimination:</span> Approximately 60% recovered in urine as penciclovir. <span class="typehead">Half-Life:</span> Penciclovir 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline CBC and routine blood chemistry studies prior to and after short courses of therapy; periodically during
            prolonged treatment.
         </li>
<li>Monitor digoxin level and assess for S&amp;S of digoxin toxicity when digoxin is used concurrently with famciclovir.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse effects and report those that are bothersome to physician.</li>
<li>Be aware that a full therapeutic response may take several weeks.</li>
<li>Report S&amp;S of hypersensitivity immediately to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>